ProCE Banner Activity

IMmotion151: Patient-Reported Outcomes With First-line Atezolizumab + Bevacizumab vs Sunitinib in Treatment-Naive Metastatic RCC

Slideset Download
Conference Coverage
All assessed patient-reported outcomes favored first-line therapy with atezolizumab + bevacizumab over sunitinib in mRCC.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen